Moors & Cabot’s Transmedics TMDX Stock Holding History

Moors & Cabot’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,077	Closed	-$206K	–	996
2026 Q1	$206K	Buy	2,077 +211	+11%	+$27.5K	0.01%	850
2025 Q4	$227K	Hold	1,866	–	–	0.01%	810
2025 Q3	$209K	Buy	+1,866	New	+$218K	0.01%	825

Other funds holding TMDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Moors & Cabot's TMDX Position: Q2 2026 in Review

Moors & Cabot sold out of Transmedics (TMDX) in Q2 2026, closing a stake of 2,077 shares — an estimated $206K sold.

Moors & Cabot first reported a position in TMDX in Q3 2025 and held it in 3 quarters. The position peaked at $227K in Q4 2025. 375 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

Moors & Cabot reported no remaining Transmedics position as of Q2 2026 after selling out during the quarter.
Moors & Cabot sold 2,077 Transmedics shares in Q2 2026, an estimated $206K.
Moors & Cabot first reported a position in Transmedics in Q3 2025 and held it in 3 quarters.
Moors & Cabot's Transmedics position peaked at $227K in Q4 2025.
375 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.